Update on gingival overgrowth by cyclosporine a in renal transplants

Organ transplantation procedures necessitate the use of immunosuppressant drugs. Immunosuppressant therapy is prescribed in treatment of autoimmune diseases and prevention of organ transplants rejection. The increased use of these medications has focused attention on the specific toxicities and side-effects associated. Since 1965, Merrill performed in human beings the renal transplant and now it is considered a routine therapy for the treatment of irreversible renal failures. After renal transplantation, it is mandatory beginning immunosuppressant therapy in order to create a condition in which lymphocytes are not active, to avoid renal transplant rejection.

Cyclosporine A (CsA) has been the primary tool to prevent the rejection of organ transplants. The clinical use of CsA is often complicated by several well documented side effects including gingival overgrowth.